



TB2018

Bridging the TB and HIV communities

Amsterdam, the Netherlands | 22 July 2018

Organized by



Stop TB Partnership



USAID
FROM THE AMERICAN PEOPLE

07:30 – 08:00 Registration and welcome coffee**08:00 – 08:15 The TB and HIV syndemics**

Session co-chairs: Lucica Ditiu, Switzerland, & Yogan Pillay, South Africa

| | | |
|---------------|---|--|
| 08:00 – 08:15 | Welcome to Amsterdam <ul style="list-style-type: none"> What can we expect from TB 2018? Is this the right discussion at the right time? | <ul style="list-style-type: none"> Frank Cobelens, the Netherlands Adeeba Kamarulzaman, Malaysia |
|---------------|---|--|

08:15 – 09:25 Setting the stage towards the UN High-Level Meeting on TB

Session co-chairs: Lucica Ditiu, Switzerland, & Yogan Pillay, South Africa

| | | |
|---------------|---|--|
| 08:15 – 08:25 | Opening address: TB and HIV in 2018 <ul style="list-style-type: none"> Reflecting on the challenges to end TB and HIV | <ul style="list-style-type: none"> Aaron Motsoaledi, South Africa |
| 08:25 – 08:35 | Towards universal health coverage for TB and HIV <ul style="list-style-type: none"> How do we drive down leading infectious diseases while striving for universal health coverage? TB as a marker for achievements in universal health coverage | <ul style="list-style-type: none"> Soumnya Swaminathan, Switzerland |
| 08:35 – 09:25 | Discussion: Towards the UN High-Level Meeting on TB <ul style="list-style-type: none"> How can the UN High-Level Meeting on TB accelerate the TB response? Why is a multi-sectoral approach for TB important? How can affected communities and civil society support a successful UN High-Level Meeting on TB? How do we support countries to achieve their national plans through targeted interventions? | Moderator: <ul style="list-style-type: none"> James Chau, China Panellists: <ul style="list-style-type: none"> Eric Goosby, USA Evaline Wanjiru Kibuchi, Kenya Yousaf Shaikh, Pakistan William Steiger, USA |

09:25 – 10:50 Preventive TB therapy for people living with HIV

Session co-chairs: Lele Rangaka, South Africa & Nick Paton, Singapore

| | | |
|---------------|---|--|
| 09:25 – 09:40 | WHO Consolidated guidelines for TB preventive treatment <ul style="list-style-type: none"> Updates and highlights | <ul style="list-style-type: none"> Annabel Baddeley, Switzerland |
| 09:40 – 09:55 | New avenues in TB preventive therapy <ul style="list-style-type: none"> Current IPT coverage and health system constraints Alternative regimens (e.g., 3HP and 1HP) Short-course TB preventive regimens Preventive therapy for drug-resistant TB | <ul style="list-style-type: none"> Dick Chaisson, USA |
| 09:55 – 10:10 | Community good practice: Preventing TB/HIV co-infection <ul style="list-style-type: none"> Service delivery Treatment literacy Advocacy | <ul style="list-style-type: none"> Dean Lewis, India |
| 10:10 – 10:50 | Discussion: Bringing TB prevention to scale <ul style="list-style-type: none"> What is the role of civil society in creating demand for and supporting adoption of TB preventive therapy? Implementation and scale up of TB prevention: Is it the role of HIV or TB programmes? What are research priorities for TB prevention and how can we stimulate scale up of preventive therapy? How can the UN High-Level Meeting on TB support the scale up of TB prevention? | Moderator: <ul style="list-style-type: none"> Linda-Gail Bekker, South Africa Panellists: <ul style="list-style-type: none"> Gavin Churchyard, South Africa Maureen Kamene, Kenya Abdulai Sesay, Sierra Leone Elvi Siahaan, Indonesia |

10:50 – 11:20 Break & poster viewing**11:20 – 13:00 Unpacking TB/HIV mortality**

Session co-chairs: Emilio Emini, USA & Norbert Ndjeka, South Africa

| | | |
|---------------|--|---|
| 11:20 – 11:35 | Mortality and the cascade of TB care in people living with HIV <ul style="list-style-type: none"> What do we know about TB/HIV mortality? Where does TB/HIV mortality occur in the cascade of care? | <ul style="list-style-type: none"> Alberto Garcia-Basteiro, Mozambique |
| 11:35 – 11:50 | Barriers to accessing new (TB/HIV) diagnostics <ul style="list-style-type: none"> Impact of new TB/HIV diagnostics on mortality (LAM, Xpert Ultra, CRP triaging), including those in the development pipeline Expansion of TB and HIV testing to facilitate early diagnosis: Lessons from Asia | <ul style="list-style-type: none"> Mishal Khan, UK |
| 11:50 – 12:05 | Addressing challenges in scaling up TB and HIV treatment integration <ul style="list-style-type: none"> Strengthening the HIV treatment cascade in TB patients Which models of care work best? | <ul style="list-style-type: none"> Alison Grant, South Africa |
| 12:05 – 12:20 | The convergence of the MDR-TB and HIV co-epidemics <ul style="list-style-type: none"> Global situation and focus on hotspots The case of Eastern Europe Scaling up second-line treatment | <ul style="list-style-type: none"> Jens Lundgren, Denmark |
| 12:20 – 13:00 | Discussion: Explaining our failure to reduce TB/HIV mortality <ul style="list-style-type: none"> Why is TB screening among people living with HIV not meeting targets? If TB is the leading killer of people living with HIV, why are there not more HIV resources focused on TB? Why have we failed to reduce TB/HIV mortality? What more can be done to reduce TB/HIV mortality? How can the UN High-Level Meeting on TB support efforts to reduce TB/HIV mortality? | Moderator: <ul style="list-style-type: none"> Michael Kimerling, Netherlands Panellists: <ul style="list-style-type: none"> Maura Elaripe, Papua New Guinea Paula Fujiwara, USA Harriet Mayanja-Kizza, Uganda Vitaly Tkachuck, Ukraine Georgia White, USA |

13:00 – 14:15 Lunch & poster viewing - Poster category: PINK

TB 2018 features several high-level speakers, including Eric Goosby, Soumnya Swaminathan, Yogan Pillay and Aaron Motsoaledi.

14:15 – 15:30 START OF PARALLEL SESSIONS -----

14:15 – 15:30 **Parallel Session A: Driving the accountability framework from the top down and bottom up** – *Main meeting room (Elicium 1)*

Session co-chairs: Aaron Oxley, UK, & Diana Weil, Switzerland

| | | |
|---------------|--|--|
| 14:15 – 14:30 | Learning from community experience with HIV high-level meetings <ul style="list-style-type: none"> • HIV high-level meetings: Highs and lows of community engagement and influence • How can community drive the agenda for the TB High-Level Meeting? | <ul style="list-style-type: none"> • Mary Ann Torres, Canada |
| 14:30 – 14:45 | Accountability and targets: Lessons learned from disease control programmes for other infectious diseases <ul style="list-style-type: none"> • Lessons learned from other disease control programmes (e.g., malaria, leprosy) • Why is an accountability framework needed and what should it achieve? | <ul style="list-style-type: none"> • Richard Hayes, UK |
| 14:45 – 15:00 | Building governmental support <ul style="list-style-type: none"> • How can Ministers of Health obtain political support from other sectors of the government? | <ul style="list-style-type: none"> • Yogan Pillay, South Africa |
| 15:00 – 15:15 | Monitoring the accountability framework <ul style="list-style-type: none"> • Community perspective | <ul style="list-style-type: none"> • Blessi Kumar, India |
| 15:15 – 15:30 | Holding governments accountable <ul style="list-style-type: none"> • How do we hold governments accountable on barriers to care (including human rights, stigma and discrimination)? | <ul style="list-style-type: none"> • Lynette Mabote, South Africa |

14:15 – 15:30 **Parallel session B: TB/HIV in prisons**

– *Parallel meeting room (D201)*

Session co-chairs: Sarabjit Chadha, India, & Masoud Dara, Denmark

| | | |
|---------------|--|--|
| 14:15 – 14:30 | Closed settings as reservoirs and drivers for community transmission of TB <ul style="list-style-type: none"> • Recent insights on TB transmission biology • Ways to identify transmission hotspots • Potential for intervention and concrete applications • Is community infection control feasible? | <ul style="list-style-type: none"> • Robin Wood, South Africa |
| 14:30 – 14:45 | Implementing TB control in prisons with high TB burden <ul style="list-style-type: none"> • What is best practice and what are the main challenges? | <ul style="list-style-type: none"> • Natavan Alikhanova, Azerbaijan |
| 14:45 – 15:00 | Community perspective on TB care in prisons <ul style="list-style-type: none"> • What does TB care in prisons really look like? | <ul style="list-style-type: none"> • Karabo Rafube, South Africa |
| 15:00 – 15:30 | Discussion: Addressing TB in closed settings <ul style="list-style-type: none"> • What is needed to fully address TB in closed settings? • How can the UN High-Level Meeting on TB incentivize UN Member States to seriously address TB in prisons? | Moderator: <ul style="list-style-type: none"> • Rick Altice, USA Panellists: <ul style="list-style-type: none"> • All speakers • Gumisayi Bonzo |

----- END OF PARALLEL SESSIONS -----

15:30 – 16:00 **Break & poster viewing**

16:00 – 17:45 Moving towards sustainable financing

Session co-chairs: Cheri Vincent, USA, & José Luis Castro, France

| | | |
|---------------|--|--|
| 16:00 – 16:10 | Funding gaps to realize the Global Plan to End TB <ul style="list-style-type: none"> Estimated needs Constraints | <ul style="list-style-type: none"> Sahu Suvanand, Switzerland |
| 16:10 – 16:20 | Financing TB and HIV control in high-burden countries <ul style="list-style-type: none"> Snapshot of the current situation Efficiencies and cost effectiveness Options for domestic financing | <ul style="list-style-type: none"> Anna Vassall, UK |
| 16:20 – 16:40 | Alternative financing models <ul style="list-style-type: none"> How do we mobilize more resources through multi-laterals, bi-laterals, national and private financing? | <ul style="list-style-type: none"> Joanne Carter, USA |
| 16:40 – 16:55 | Catastrophic costs of TB and HIV: Community perspective <ul style="list-style-type: none"> Real-life consequences for affected populations | <ul style="list-style-type: none"> Thato Mosidi, South Africa |
| 16:55 – 17:10 | Health insurance and social protection <ul style="list-style-type: none"> How do we use domestic resources more efficiently and ensure that universal TB and TB/HIV services are covered? | <ul style="list-style-type: none"> Elaine Baruwa, USA |
| 17:10 – 17:45 | Discussion: Moving towards sustainable financing <ul style="list-style-type: none"> How can we ensure adequate financing for the TB response? How can the UN High-Level Meeting on TB help us move towards sustainable financing? | Moderator: <ul style="list-style-type: none"> Chris Collins, USA Panellists <ul style="list-style-type: none"> All speakers David Wilson, USA |

17:45 – 19:00 Closing: Moving forward towards the UN High-Level Meeting on TB and beyond

Session co-chairs: Frank Cobelens, the Netherlands, & Adeeba Kamarulzaman, Malaysia

| | | |
|---------------|--|---|
| 17:45 – 18:30 | Discussion: The urgency of overcoming the bottlenecks to end TB and HIV <ul style="list-style-type: none"> Political, financial and access barriers Country progress and challenges Looking forward to the UN High-Level Meeting on TB | Moderator: <ul style="list-style-type: none"> Mark Dybul, USA Panellists: <ul style="list-style-type: none"> Timur Abdullaev, Uzbekistan Jeffry Acaba, Philippines David Mametja, South Africa Peter Sands, Switzerland Kitty van Weezenbeek, Netherlands |
| 18:30 – 18:45 | Call to action towards the UN High-Level Meeting on TB <ul style="list-style-type: none"> The top five elements to consider at the UN High-Level Meeting on TB | <ul style="list-style-type: none"> Lucica Ditiu, Switzerland Yogan Pillay, South Africa |
| 18:45 – 19:00 | Closing statement by the Deputy President of South Africa | <ul style="list-style-type: none"> David Mabuza, South Africa |

19:00 – 20:30 Reception & poster viewing - Poster category: ORANGE

SERVICE DELIVERY

1) Addressing high burden of tuberculosis in First Nations communities through the high incidence strategy: An evaluation project in northern Saskatchewan, Canada

S. Mahmoodi, S. Hourigan, I. Khan, N. Ndubuka

2) Collaborative efforts for improving TB services; A case of PS Kenya in Nyanza region of Kenya, Private sector

C. Kanari

3) Community Task Forces Making a difference: Increasing TB Case Notification Rates through Community-led TB Campaigns (TBC) in 11 Regions in Tanzania

G. Asuquo, Y. Ferguson, K. Achebe, M. Imran

4) Engaging private medical practitioners for early HIV screening and treatment initiation of tuberculosis (TB) patients in Maharashtra

J. Thakker, P. Bogam, R. Taralekar, S. Vijayan, L. Sadasivan, R. Chopra, A. Ali, D. Gangurde, S. Acharya

5) Funding for HIV/AIDS and TB: producing evidence for a successful donor transition in Cambodia

F. Sophie, B. Johns, H. Nguyen

6) How does integrating HIV and TB services affect health outcomes for HIV-TB co-infected patients in Ukraine? Results from an impact evaluation

S. Agarwal, S. Curtis, S. Mullen, M. Skiles, Z. Charyeva, K. Brugh, C. Suchindran, O. Zaliznyak, T. Senik, P. Brodish, S. Eagan

7) Human rights barriers to access TB and TB/HIV perceptions by mine workers in 10 Southern Africa Countries (Botswana, Lesotho, Malawi, Mozambique, Namibia, South Africa, Swaziland, Tanzania, Zimbabwe and Zambia)

L. Busang, B. Fidzani, B. Mbambo, M. Ndhlahambi, J. Mafeni, F. Mwangemi

8) Implementation of HIV Testing Status of TB cases and ART coverage: A descriptive analysis of PEPFAR and National data in 15 countries in East and Southern Africa

E. Noykhovich, C. Nichols, J.S. Cavanaugh

9) Improved utilization of the National Pediatric and Adolescent HIV/AIDS/TB Call Center through targeted marketing: lessons from Baylor-Uganda

F.F. Tendo, L. Engurat, J. Balungi Kanywa., A. Kekitinwa

10) Increasing TB case detection and treatment among street children in the slums of Kampala District; the case of Kamwokya Christian Caring Community (KCCC)

N. Seruma, A. Namugwere, KCCC Study Group

11) Low ART coverage of TB/HIV Infected Patients in Central Asia: Results from Kazakhstan and Kyrgyzstan

Y. Kodussova, T. Ellman, A. Deryabina

12) Probabilistic recorded linkage as a tool to improve TB-HIV coinfection surveillance in Brazil

K. Andrade, C.O. Dantas, D.M. Pelissari, M.S. Rocha, L.A. Nascimento Júnior, P.O. Bartholomay, D. Arakaki, R.A. Ribeiro, R. Coelho, A.R.C.d. Cunha, G.F.M. Pereira

13) Risk factors of recurrent TB disease in a setting of high HIV prevalence

S. Hermans, N. Zinyakatira, J. Caldwell, F. Cobelens, A. Boulle, R. Wood

14) Safety and efficacy of dolutegravir-based ART in TB/HIV co-infected adults at week 48

K. Dooley, R. Kaplan, T. Mwelase, B. Grinsztejn, E. Ticona, M. Lacerda, O. Sued, E. Belonosova, M. Ait-Khaled, K. Angelis, D. Brown, R. Singh, C. Talarico, A. Tenorio, M. Keegan, M. Aboud

15) Strengthening HIV and tuberculosis surveillance through intensified case finding in a prison in North-East India, 2017

T. Bhatnagar, M. Ralte, L. Ralte, Chawnglungmuana, L. Sundaramoorthy, L. Chhakchhuak

16) Trend analysis of HIV/TB integrated services utilization and coverage in Uganda Harm Reduction Referral Points in Kampala, Gulu, Mbarara and Mbale

W.T. Lotic, E. Muhwezi, C. Baguma, S. Ajuna

17) Tuberculosis testing and treatment among people who use drugs in Abidjan: results and perspectives for a community-based approach implemented in Abidjan, Côte d'Ivoire

A. Bernier, G. Colin, N. Luhmann, L. N'zi, S. Houndji, A. Assoumou2, D. Ramatou, J. Bouscaillou, L.-H. Adjahi, J. Evanno, R. Boulet, C. Doumenc-Aïdara, C. Dézé, A. Kouamé, R. Kouassi N'Guessan, Presenter: E. Wisse

TB PREVENTIVE THERAPY & LATENT TB INFECTION —

18) Estimating Latent Tuberculosis Infection Prevalence in the United States: Back-Calculation from Active TB Cases

A. Mirzazadeh, I.E. Fellows, H. Ashki, A. Parriott, A. Readhead, P. Barry, J. Flood, T.R. Navin, A.N. Hill, S. Reynolds, S. Marks, D. McCabe, J. Mermin, J.G. Kahn, P.B. Shete

19) Health-related quality of life in the A5274 trial (REMEMBER) of empirical tuberculosis (TB) therapy versus isoniazid preventive therapy (IPT) in adult outpatients with advanced HIV

R. Lando, X. Sun, S. Miyahara, M. Hosseinpour, G. Bisson, J. Kumwenda, A. Gupta, M. Nyirenda, K. Katendey, T. Torres, N. Suryavanshi, F. Beulah, N.S. Shah, A5274 Study Group

20) Policy implementation gap of Isoniazid Preventive Therapy (IPT) among people living with HIV in limited resource setting: lessons from Nepal

K. Deuba, U. Shrestha, B. Rawal, R.P. Khanal, R.K. Bhattarai, B.D. Pandey, R. Shrestha, A.M. Ekstrom

21) Status of provision of Isoniazid Preventive therapy for People Living with HIV and lessons learnt from the challenges in the programmatic implementation and expansion in India

D. Balasubramanian, M. Gorla, R. Rao, N. Kumar, M. Bamrotiya, K.S. Sachdeva, R.S. Gupta, S.D. Khaparde, K.K. Rade

22) Task shifting increased IPT uptake and completion among people living with HIV in secondary health facilities southeast Nigeria

O. Onyediniachi, O. Eghaghara, O. Adebayo, A. Eyo, G. Odotuga

23) The importance and clinical relevance of baseline LTBI screening in HIV patients

N.S. Wong, C.C. Leung, K. Chan, W.K. Chan, A. Lin, S.S. Lee

24) Toward Improved IPT Implementation for Adolescents Living with HIV in Swaziland: Elucidating the Barriers through the Theory of Planned Behavior

A. Kay, N. Thivalapill, S. Donald, P. Fuentes, N. Dlamini, P. Ustero, L. Adams, A. Mandalakas

25) Towards 95% completion rates of Isoniazid preventive therapy in resource limited setting; case of Amref Kibera community health centre, Nairobi, Kenya MDR-TB / TB / HIV co-infection

Z. Muiruri Njogu, D. Wanyama, M. Mungai, S. Karanja, D. Dianga

26) Tuberculosis preventive therapy in PEPFAR countries

J. Cavanaugh, J. Brown, A. Sanicki, H. Meri, G. Siberry

DIAGNOSTICS —

27) Early Detection of Tuberculosis Consortium (E-DETECT TB)

G. de Vries, I. Abubakar, L. Barcellini, C. Batt, D. M. Cirillo, S. Collin, A.-M. Duca, K. Lönnroth, V. Marchese, A. Matteelli, J. Nederby Öhd, A. Story, D. Zenner

28) Enhancement of the INSHI case definition for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome using latent class analysis

C. Stek, J. Buyze, J. Menten, C. Schutz, F. Thienemann, L. Blumenthal, G. Maartens, T. Boyles, R.J. Wilkinson, G. Meintjes, L. Lynen

29) Evaluation of a Prototype cobas®MTB assay for use on the cobas® 6800/8800 Systems for the detection of Mycobacterium tuberculosis in a high burden HIV patient population

L. Scott, A. David, J. Furrer, F. Schneider, L. Govender, S. Kumar, F. Bastos, S. Lange, P. Loetscher, N. Martinson, E.M. Marlowe, W. Stevens

30) Expanding use of TB-LAM for HIV+ individuals with CD4< 200: Evidence from MSF operational research and beyond

K. England, E. Fajardo, G. Ferlazzo, H. Hueriga

31) Roll out and scale up of WHO-endorsed TB diagnostic technologies to diagnose TB and MDR-TB in African: from Stop TB to End TB Strategy era

J.D.D. Iragena, F. Jallow, M. Gasana, H. Lago

32) Selective Immune Cell Depletion of Mycobacterium Tuberculosis (Mtb) in Whole-blood Bactericidal Assay (WBA)

G.B. Cross, B.C. Yeo, M.C. Tan, R. Verma, Q. Lu, N.I. Paton

33) The effect of HIV status on the identification of differentially culturable tubercle bacilli (DCTB) during treatment of drug susceptible tuberculosis

J.S. Peters, A. Mc Ivor, A. Papadopoulos, T. Masangana, B.G. Gordhan, K. Otworld, Z. Waja, N. Martinson, F. Shahim, B.D. Kana

34) Using a targeted approach to boost TB case-finding among vulnerable Children- The SMILE Experience

C. Anojé, T. Lan, E. Olashore, M. Bebia, A. Efuntoye, O. Temitayo, P. Gado

35) Utility of gene Xpert MTB/RIF as a screening assay for tuberculosis in HIV-infected patients from a rural setting of Rakai district, Uganda

R. Muwanika

36) Yield and efficiency of novel intensified tuberculosis case-finding algorithms for people living with HIV

C. Yoon, F. Semitala, L. Asege, J. Katende, S. Mwebe, A. Andama, E. Atuhumuza, M. Nakaye, D. Armstrong, D. Dowdy, C. McCulloch, M. Kanya, A. Cattamanchi

MDR-TB & TB/HIV CO-INFECTION

37) Clinical outcomes with bedaquiline use when substituted for second-line injectable agents in multidrug resistant tuberculosis: a retrospective cohort study

Y. Zhao, K. Manning, A. Stewart, T. Fox, N. Tiffin, A. Boule, V. Mudaly, Y. Kock, G. Meintjes, S. Wasserman

38) Clinical predictors of Mycobacterium tuberculosis bacteremia in a contemporary cohort of HIV-infected patients in Rio de Janeiro, Brazil

J. Moreira, R. Castro, C. Lamas, M.C. Lourenco, S. Ribeiro, B. Grinsztejn, V.G. Veloso

39) Data driven insight on TB and HIV co-infections amongst high risk groups in Zimbabwe: TaS4TB 2017 operational year

T. Sengai, F. Kavhenga, G. Shumba

40) Improving survival among HIV positive MDR-TB patients with unsuccessful outcomes after the shorter MDR-TB regimen in high HIV-burden setting. Lessons learnt from the field

D. Vambe, J. Furin, C. Wawa Mbo, O. Kasay Maha, M.L. Vilane, T. Dlamini, S.M. Haumba

41) Mining areas, one of the hotbeds of tuberculosis and HIV AIDS. Case of mining areas in eastern Democratic Republic of Congo

O. Rusumba, N. Nyakabwa, V. Bola, F. Birembano, I. Alain

42) Poor Treatment outcome and higher mortality rate among TB/HIV co-infected patients compared to TB without HIV infected patients

S. Gatechompol, J. Sophonphan, K. Kawkitinarong, G. Suwanpimolkul, P. Kateruttanakul, W. Manosuthi, S. Ubolyam, S. Kerr, A. Avihingsanon, K. Ruxrungtham

43) TB-HIV program monitoring in PEPFAR-supported countries: screening, prevention, and treatment results for children and adults, October 1, 2016 - September 30, 2017

K. O'Connor, V. Ryan, R. Golin, C. Nichols, G. Anyalechi, H. Kirking, M. Patel

44) Tuberculosis and HIV co-infection in the European Union: Epidemiology and tuberculosis treatment outcomes

M. van der Werf, C. Ködmön

45) Tuberculosis incidence, risk factors and associated mortality in adults living with HIV, on antiretroviral therapy, in Thailand: a 12-year cohort study

A. Duclau, N. Salvadori, A. Nechba, S. Kawilapat, E. Cercier, P. Traisathit, S. Khusuwan, P. Kanjanavikai, M. Techapornroong, S. Thongpaen, Y. Buranawanitchakorn, R. Lertkoonalak, P. Sang-a-gad, S. Le Coeur, M. Lallemand, N. Ngo-Giang-Huong, G. Jourdain



Organized by



Stop TB Partnership



USAID
FROM THE AMERICAN PEOPLE